Most Recent Articles by Debra Hughes, MS
The FDA has granted accelerated approval for the agency's first tissue/site agnostic indication to pembrolizumab.
The FDA granted regular approval to pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following chemotherapy.
It's unclear whether the FDA will revoke its May 2016 approval of atezolizumab, which was based on tumor response rate and duration of response in the phase 2 open-label IMvigor210 study.
Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy.
The US Food and Drug Administration has approved avelumab for locally advanced or metastatic urothelial carcinoma.
More Articles by Debra Hughes, MS
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|